Surgical decision-making after neoadjuvant chemotherapy in pancreatic ductal adenocarcinoma
Huisong Lee · 2025
Read Surgical decision-making after neoadjuvant chemotherapy in pancreatic ductal adenocarcinoma by Huisong Lee (2025) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-12685454.txt.
Description
Huisong Lee reviews how surgeons should decide on operating after chemotherapy for pancreatic cancer, in a 2025 paper. Chemo before surgery, once reserved for borderline cases, is now used even when tumors look removable, since early systemic treatment helps many patients. The hard part is judging response: scans often cannot tell dead tumor from scar tissue.
Lee weighs the tools that fill the gap. Blood marker CA19-9 works best as a trend, with a drop of 70 percent or more tied to better survival. Tumor DNA in the blood can reveal leftover disease, and clearing it after surgery predicts longer survival. The review argues for combining imaging with these biological signals instead of trusting scans alone.
Catalog record
| CREATOR | Huisong Lee |
|---|---|
| YEAR | 2025 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 5 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |